Extension of Haleon Licensing and Supply Agreement

Summary by AI ^BETAClose X

Wellnex Life Limited has announced the extension of its licensing and supply agreement with Haleon UK Trading Services Ltd for soft gel liquid paracetamol products. The agreement, originally signed on March 16, 2022, has been successfully extended until March 16, 2027, continuing Wellnex Life's partnership in supplying innovative analgesic liquid soft gels for Haleon's global brands.

Disclaimer*

Wellnex Life Limited

02 April 2026

ASX/AIM Announcement

2 April 2026

Extension of Haleon Licensing and Supply Agreement

Wellnex Life Limited (ASX/AIM: WNX) ("Wellnex Life" or the "Company") is pleased to announce that the Company, through its wholly owned subsidiary BSPS Aust Pty Ltd, has signed an extension to the existing licensing and supply agreement (the "Agreement") originally entered into on 16 March 2022 between the Company, Haleon UK Trading Services Ltd ("Haleon UK") and Olive Pharmascience Ltd. The Agreement, for the supply to Haleon UK of soft gel liquid paracetamol products, has been extended until 16 March 2027.

Eric Jiang Interim Executive Chairman said, "The Company is proud to continue its global partnership with Haleon, supporting their global brands with our innovative analgesic liquid soft gels."

This ASX/AIM announcement has been authorised by the Board of Wellnex Life Limited (ASX/AIM:WNX).

--- END ---

For further information, please contact:

Wellnex Life Limited (ASX/AIM:WNX)

Eric Jiang

Interim Executive Chairman

E: eric.j@wellnexlife.com.au

UK Investors

Strand Hanson (Financial & Nominated Advisor)

James Harris / Richard Johnson Tel: +44 (0) 20 7409 3494

Orana Corporate LLP (Joint Broker) swykeham@oranacorp.com

Sebastian Wykeham

S.P. Angel Corporate Finance LLP (Joint Broker) Tel: +44 (0)20 3470 0470

David Hignell / Vadim Alexandre

To learn more, please visit: https://wellnexlife.com.au/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END